Iasibon 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0024 
Minor change in labelling or package leaflet not 
03/10/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0023/G 
This was an application for a group of variations. 
11/07/2022 
n/a 
B.I.b.1.c - Change in the specification parameters 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
N/0022 
Minor change in labelling or package leaflet not 
10/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/11/2020 
12/11/2021 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0020 
Minor change in labelling or package leaflet not 
03/04/2019 
12/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0019 
Minor change in labelling or package leaflet not 
28/06/2018 
12/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0018 
Minor change in labelling or package leaflet not 
18/10/2016 
14/11/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0017 
Minor change in labelling or package leaflet not 
21/07/2016 
14/11/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/11/2015 
14/11/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
R/0015 
Renewal of the marketing authorisation. 
23/07/2015 
30/09/2015 
SmPC and PL 
Based on the review of the available information the CHMP 
is of the opinion that the quality, the safety and the efficacy 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considers that the 
benefit/risk profile of Iasibon remains favourable. The 
CHMP is of the opinion that the renewal can be granted 
with unlimited validity. 
IA/0014 
A.7 - Administrative change - Deletion of 
11/05/2015 
n/a 
manufacturing sites 
IB/0012/G 
This was an application for a group of variations. 
08/08/2014 
08/07/2015 
SmPC 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/07/2014 
08/07/2015 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0011 
Minor change in labelling or package leaflet not 
07/04/2014 
22/05/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0010 
C.I.8.a - Introduction of or changes to a summary of 
16/10/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0007 
To add a new manufacturer of the active substance. 
27/06/2013 
n/a 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
supported by an ASMF 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/05/2013 
22/05/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
N/0008 
Minor change in labelling or package leaflet not 
28/02/2013 
22/05/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0006 
B.II.d.2.d - Change in test procedure for the finished 
07/11/2012 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
N/0005 
Minor change in labelling or package leaflet not 
18/05/2012 
04/07/2012 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0004 
Minor change in labelling or package leaflet not 
08/02/2012 
04/07/2012 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0002/G 
This was an application for a group of variations. 
14/12/2011 
04/07/2012 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0003/G 
This was an application for a group of variations. 
08/12/2011 
n/a 
C.I.9.i - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
